Paliperidone

Paliperidone
Clinical data
Trade names	Invega, others
Other names	9-hydroxyrisperidone; PP; PP1M; PP3M; PP6M; JNS-010; RO-92670; RO92670
AHFS/Drugs.com	Monograph
MedlinePlus	a607005
License data	US DailyMed: Paliperidone;
Pregnancy; category	AU: B3;
Routes of; administration	By mouth, intramuscular
Drug class	Atypical antipsychotic
ATC code	N05AX13 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C1 (Other controlled substances); CA: ℞-only; US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	28% (oral)
Elimination half-life	23 hours (by mouth)
Excretion	1% unchanged in urine 18% unchanged in feces
Identifiers
	IUPAC name (RS)-3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one;
CAS Number	144598-75-4 ; as palmitate: 199739-10-1;
PubChem CID	115237; as palmitate: 9852746;
DrugBank	DB01267 ; as palmitate: DBSALT001464;
ChemSpider	7978307 ; as palmitate: 8028457;
UNII	838F01T721; as palmitate: R8P8USM8FR;
KEGG	D05339 ; as palmitate: D05340;
ChEBI	CHEBI:82978 ; as palmitate: CHEBI:83807;
ChEMBL	ChEMBL1621 ; as palmitate: ChEMBL2107360;
ECHA InfoCard	100.117.604
Chemical and physical data
Formula	C23H27FN4O3
Molar mass	426.492 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C/1N5/C(=N\C(=C\1CCN4CCC(c3noc2cc(F)ccc23)CC4)C)[C@H](O)CCC5;
	InChI InChI=1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3/t19-/m1/s1 ; Key:PMXMIIMHBWHSKN-LJQANCHMSA-N ; ; as palmitate: InChI=1S/C39H57FN4O4/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-18-36(45)47-34-17-16-24-44-38(34)41-29(2)32(39(44)46)23-27-43-25-21-30(22-26-43)37-33-20-19-31(40)28-35(33)48-42-37/h19-20,28,30,34H,3-18,21-27H2,1-2H3; Key:VOMKSBFLAZZBOW-UHFFFAOYSA-N;
	(what is this?) (verify)

Paliperidone, sold under the brand name Invega among others, is an atypical antipsychotic. It is used for the treatment of schizophrenia and schizoaffective disorder. It is marketed by Janssen Pharmaceuticals.

Paliperidone was approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia in December 2006, and in the European Union in June 2007. Paliperidone palmitate is a long-acting injectable formulation of paliperidone palmitoyl ester. It is on the World Health Organization's List of Essential Medicines. Paliperidone is available as a generic medication.